Portola Pharma (PTLA) Tops Q3 EPS by 54c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Portola Pharmaceuticals (PTLA) PT Lowered to $45 at Cowen
November 8, 2018 8:41 AM ESTCowen analyst Phil Nadeau lowered the price target on Portola Pharmaceuticals (NASDAQ: PTLA) to $45.00 (from $50.00) while maintaining a Outperform rating.
... MorePortola Pharmaceuticals (PTLA) PT Lowered to $30 at Oppenheimer
November 8, 2018 8:29 AM ESTOppenheimer analyst Jay Olson lowered the price target on Portola Pharmaceuticals (NASDAQ: PTLA) to $30.00 (from $60.00) while maintaining a Outperform rating.
Olson commented, "PTLA introduced its new CEO and provided a business update in the context of 3Q results. Andexxa revenue at... More
Portola Pharmaceuticals (PTLA) PT Lowered to $30 at Credit Suisse
November 8, 2018 8:10 AM ESTCredit Suisse analyst Vamil Divan lowered the price target on Portola Pharmaceuticals (NASDAQ: PTLA) to $30.00 (from $34.00) while maintaining a Neutral rating.
... More